Dagibatran
Therapeutic agent (verify pharmacological class)
What it is used for
Prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery. Clinical selection for Dagibatran should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
Warnings
Elderly; bodyweight less than 50 kg; recent surgery; anaesthesia with postopera- tive indwelling epidural catheter [risk of paralysisgive initial dose at least 2 hours after catheter removal and monitor neurological signs]; bacterial endocarditis [increased risk of bleed- ing]; bleeding disorders; active gastrointestinal ulceration; concomitant use of drugs that increase risk of bleeding.
Possible side effects
Adverse reactions vary by agent. Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes). Report suspected ADRs via national pharmacovigilance channels.
Storage
Store as labelled. Keep out of reach of children.
No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.